- Apnimed aspires for up to $160M IPO as sleep apnea pill launch nearsApnimed has detailed its plans for an initial public offering, with the biotech intending to raise as much as $160 million to fund the launch of its sleep apnea pill.Fierce Biotech · 1d ago↗ source
- MapLight shares sink on mixed phase 2 schizophrenia readoutMapLight Therapeutics’ stock plummeted more than 60% this morning after the neuro outfit dropped mixed results for a phase 2 trial of its experimental schizophrenia treatment.Fierce Biotech · 1d ago↗ source
- FDA approves Freenome colorectal cancer blood test to be marketed by AbbottThe FDA has approved Freenome’s new blood-based colorectal cancer test, SimpleScreen CRC, which Abbott will exclusively market in the U.S.Fierce Biotech